Oncorine (recombinant human adenovirus type 5)

These findings indicate that PRXL2B promotes malignant phenotypes in HCC and may modulate H101 efficacy through the PI3K/AKT/PD-L1 axis. Targeting PRXL2B may therefore represent a potential strategy to enhance the therapeutic efficacy of oncolytic virus therapy in HCC.

At the most recent follow-up, there was no evidence of local recurrence or distant metastasis. This case highlights the potential of oncolytic virotherapy to enhance chemotherapy and radiotherapy effects in LARC patients.

P2, N=20, Not yet recruiting, Chongqing University Cancer Hospital

In vivo experiments further confirmed the significant antitumor effects and the favorable safety profile of H101. These findings suggest that the antitumor effects of H101 are associated with the downregulation of HPV16 E6/E7 and the activation of the p53-p21 pathway, involving both p53-dependent and p53-independent mechanisms.

The combination of H101 and APA exhibited excellent anti-HCC efficacy, which may reshape the TME partially through the IFN-γ/STAT1/PD-L1 axis. These findings provide a promising strategy to overcome resistance to ICIs in HCC treatment.

Despite the recent regulatory approvals of oncolytic viruses such as T-VEC (JS1/34.5-/47-/GM-CSF), Oncorine (H101), and Teserpaturev (G47Δ), the clinical impact of OV remains limited by its reliance on intratumoral administration. Preclinical studies demonstrate that FusOn-SD efficiently reaches tumor sites following systemic administration, exhibiting enhanced immune evasion and oncolytic potency. These findings position FusOn-SD as a promising candidate for advancing OV beyond localized injections, with the potential to transform virotherapy into a viable treatment for metastatic cancer.

P2, N=20, Not yet recruiting, West China Hospital

Subsequently, the patient was treated with an innovative regimen consisting of endoscopic intratumoral injections of Oncolytic adenovirus H101 in combination with the PD-1 inhibitor tislelizumab...The patient achieved nearly 4 months of progression-free survival and a substantial improvement in quality of life. This case highlights the potential of combining oncolytic virotherapy with PD-1 inhibition as a promising and novel personalized strategy for treating elderly patients with advanced gastrointestinal cancers who are unsuitable candidates for conventional therapies.

P=N/A, N=20, Not yet recruiting, Renji Hospital ,Shanghai Jiaotong University School Of Medicine; Renji Hospital ,Shanghai Jiaotong University School Of Medicine

P2, N=30, Not yet recruiting, Fudan University | Trial primary completion date: Jan 2026 --> Jan 2028

P2, N=25, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital

Rapid tumor shrinkage was associated with severe local inflammation and a reduction in peripheral white blood cell counts. These findings suggest that oncolytic virotherapy may elicit an abscopal effect by activating and recruiting immune cells into the tumor microenvironment.